The Ohio Clinical Trial Collaborative (OCTC)
The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.
The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.
Review the OCTC working website at: http://ohioclintrials.org.
Contact Joe Peter at 216-702-5314 for more information.
Department of Defense
The Department of Defense has announced the following new funding opportunities:
Department of the Army - USAMRAA
DoD Orthotics and Prosthetics Outcomes Research Award
U.S. Army Medical Research and Materiel Command Broad Agency Announcement (BAA) for Extramural Medical Research - Dept. of the Army -- USAMRAA — W81XWH-BAA-15-1
Opening date: October 1, 2014
Closing date: September 30, 2015
Pre-Proposals:Applicants are encouraged to submit their Pre-Proposals as early as possible in the fiscal year as funding is based on availability
Invitation to Submit: within 120 days of pre-proposal submission
Full Proposals: submitted within 90 days of the invitation
Notice of Awards: within 180 days of submission
Funding: Budgets are not capped and must reflect the scope of the work. Funding can be requested for up to 5 years.
Programs of interest:
1. Military Infectious Diseases Research
2. Combat Casualty Care Research
3. Military Operational Medicine Research
4. Clinical and Rehabilitative Medicine Research
5. Medical Biological Defense Research
6. Medical Chemical Defense Research
7. Medical Training and Health Information Sciences
8. Radiation Health Effects Research
9. Special Investment Areas
Office of Strategic Initiatives (OSI): CWRU School of Medicine's OSI can work with you to make sure that you meet the current goals and objectives of the USAMRMC.
Contact OSI: Irene Shaland - email@example.com - 216.368.4970.
The Commonwealth Fund
The Mongan Commonwealth Fund Fellowship in Minority Health Policy is a one-year, degree-granting, full-time fellowship at Harvard Medical School, Boston, beginning in July 2015.
The program is designed to prepare physicians for leadership roles in transforming health care delivery systems and promoting health policies and practices that improve access to high performance health care for racial and ethnic minorities, economically disadvantaged groups, and other vulnerable populations.
For more information and to download the brochure and application, visit the MCFF website.
Marquette University, with a generous grant from the Templeton Religion Trust, is pleased to announce a new research initiative on the topics of the self, motivation, and virtue. Approximately ten research proposals at $190,000 each will be funded through this initiative.
The grant competition has four primary aims:
1. To support innovative research on the self, motivation, and virtue.
2. To encourage methodological innovation in the study of the self, motivation, and virtue.
3. To encourage interdisciplinary team work, specifically between social science and humanities.
4. To support scholars new to the investigation of these topics or who have not received funding elsewhere. Research collaborations between younger and more established scholars are especially encouraged.
Research into character and virtue is often conducted by scholars from within a single disciplinary perspective. This disciplinary isolationism is not maximally productive of new knowledge about virtue. To ensure that research funded by this proposal closes the disciplinary gap, successful teams will be comprised of at least one humanist and one scientist who are fully and equally invested in the research project, from its inception to its completion. The aim here is to encourage awardees to think outside of their own disciplinary perspectives, and to broaden their research horizons in ways conducive to creative collaborations and results.
For more information on this extended deadline, please visit the Marquette University website or contact Marquette at: firstname.lastname@example.org.
Foundation Fighting Blindness and Harrington Discovery Institute
Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.
• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
• Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.
Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.
For more information about Foundation Fighting Blindness visit the Fighting Blindness website.
If you have news or information that you wish to have included in this
update, please send it via e-mail to Tracy Wilson-Holden at
email@example.com no later than
5 pm on the Monday of the week that the update is to be distributed. If you
know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe
to Case Research News, email your request to Tora Williams at
Please note: At the time of this transmission, all links functioned.
However, Case Research News cannot guarantee that the information will not move or be